AAM Recommends Six Areas Of Patent-Focused Reforms To Congress

By Gabrielle Wanneh / July 21, 2021 at 3:38 PM
The Association for Accessible Medicines wants Congress to focus on six areas to protect against practices that generic drug makers say delay generic and biosimilar competition. Their proposals range from preserving procompetitive settlement agreements for patents, to prohibiting rebate traps meant to delay coverage and access to lower-costing alternatives to putting an end to the spread of misinformation about generic and biosimilar products. AAM submitted the recommendations at a July 13 Senate Judiciary subcommittee hearing on boosting pharmaceutical competition through...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.